MAIA executive granted 30,000 stock options
MAIA Biotechnology, Inc. reported that its Head of Finance, Jeffrey C. Himmelreich, received a grant of stock options covering 30,000 shares of common stock.
Rhea-AI Filing Summary
MAIA Biotechnology, Inc. reported that its Head of Finance, Jeffrey C. Himmelreich, received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $1.28 per share and expire on April 10, 2036. They were granted under the company’s 2021 Equity Incentive Plan as a compensation award, not an open-market purchase. The options vest over four years, with 25% vesting on the first anniversary of the April 10, 2026 grant date and the remainder vesting monthly over the following 36 months, and represent Himmelreich’s full reported option position of 30,000 shares after this grant.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 30,000 shares
Grant/Award
1 txn
Insider
Himmelreich Jeffrey C
Role
Head of Finance
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options | 30,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Options — 30,000 contracts (Direct)
Footnotes (1)
- F1. The stock options, granted on April 10, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.
Key Figures
Options granted: 30,000 options
Exercise price: $1.28 per share
Expiration date: April 10, 2036
+4 more
7 metrics
Options granted
30,000 options
Stock options for common stock granted April 10, 2026
Exercise price
$1.28 per share
Conversion or exercise price of granted stock options
Expiration date
April 10, 2036
Expiration of the granted stock options
Underlying shares
30,000 shares
Common shares underlying the granted options
Post-grant option holdings
30,000 options
Total options held following this transaction
Initial vesting
25% at first anniversary
Portion of options vesting one year after April 10, 2026 grant date
Ongoing vesting
Remaining over 36 months
Options vest monthly after first anniversary for three years
Key Terms
Stock Options, 2021 Equity Incentive Plan, vesting schedule, underlying security
4 terms
Stock Options financial
"The stock options, granted on April 10, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan..."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
2021 Equity Incentive Plan financial
"granted on April 10, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan..."
vesting schedule financial
"vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary..."
A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.
underlying security financial
"underlying_security_title: "Common Stock", underlying_security_shares: "30000.0000""
FAQ
What insider transaction did MAIA (MAIA) report for Jeffrey C. Himmelreich?
MAIA reported a compensation grant to Head of Finance Jeffrey C. Himmelreich of stock options for 30,000 shares of common stock. These options are not an open-market purchase but an award under the company’s 2021 Equity Incentive Plan.
What is the exercise price and size of the MAIA stock options granted?
The grant consists of stock options for 30,000 shares of MAIA common stock with an exercise price of $1.28 per share. This price is the cost Himmelreich must pay per share if he chooses to exercise the options.
How do the MAIA stock options granted to Himmelreich vest over time?
The options vest on a four-year schedule. 25% of the 30,000 options vest on the first anniversary of the April 10, 2026 grant date, and the remaining options vest ratably monthly over the following 36 months, encouraging long-term service.
When do the newly granted MAIA stock options expire?
The stock options granted to Jeffrey C. Himmelreich expire on April 10, 2036. After that expiration date, any unexercised options will lapse, and he will no longer have the right to buy MAIA common shares at the $1.28 exercise price.
How many MAIA options does Himmelreich hold after this Form 4 transaction?
After this grant, Himmelreich is reported to hold 30,000 stock options directly. These options are each exercisable into one share of MAIA common stock, subject to the vesting schedule and the April 10, 2036 expiration date.
Are the MAIA options grant to Himmelreich a market buy or a compensation award?
The transaction is a grant or award acquisition of stock options, not an open-market share purchase. It was made under MAIA Biotechnology’s 2021 Equity Incentive Plan as part of Himmelreich’s compensation, with no cash paid per option at grant.
AI-generated analysis. How Rhea-AI works. Not financial advice.
